JUMBO-TIMI 26

JUMBO-TIMI 26 evaluated the efficacy and safety of prasugrel, a novel thienopyridine, compared to clopidogrel in patients undergoing PCI.

MAIN RESULTS:
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO) TIMI 26 trial

Circulation. 2005 Jun 28;111(25):3366-73.

PRESENTATIONS

TIMI 26 Slides

OTHER PUBLICATIONS

Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Am J Cardiol. 2007 Feb 1;99(3):344-8.

Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol. 2010 Oct 19;56(17):1376-85.